DENTSPLY SIRONA Inc. $XRAY Shares Acquired by Skba Capital Management LLC

Skba Capital Management LLC grew its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 14.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,140,430 shares of the medical instruments supplier’s stock after purchasing an additional 142,900 shares during the quarter. DENTSPLY SIRONA makes up about 2.0% of Skba Capital Management LLC’s portfolio, making the stock its 15th biggest holding. Skba Capital Management LLC owned 0.57% of DENTSPLY SIRONA worth $14,472,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in XRAY. AQR Capital Management LLC increased its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Norges Bank acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $39,700,000. Goldman Sachs Group Inc. increased its stake in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Brickwood Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 5,515.8% in the 3rd quarter. Brickwood Asset Management LLP now owns 1,524,074 shares of the medical instruments supplier’s stock valued at $19,340,000 after purchasing an additional 1,496,935 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in DENTSPLY SIRONA by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock worth $279,263,000 after purchasing an additional 869,566 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on XRAY shares. Barclays began coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective for the company. Mizuho boosted their price target on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, UBS Group reduced their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, DENTSPLY SIRONA has an average rating of “Hold” and an average target price of $14.42.

Insider Transactions at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $13.30 on Wednesday. The firm has a market cap of $2.66 billion, a PE ratio of -4.43, a price-to-earnings-growth ratio of 1.68 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $17.18. The business’s fifty day simple moving average is $12.52 and its 200-day simple moving average is $12.47.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. During the same period last year, the business earned $0.26 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s payout ratio is currently -21.33%.

Key Stories Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier purchased 22,445 shares on March 3 (~$14.03) after buying 27,555 shares on March 2 (~$14.24), bringing his reported holdings to ~50,000 shares — a strong insider vote of confidence that often supports the share price. Director purchase – InsiderTrades
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a meaningful upside call relative to current levels that can attract buying interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a strong negative label and supporting improved market sentiment. Zacks upgrade
• Neutral Sentiment: Mizuho lifted its price target to $16 but kept a “neutral” rating — a PT boost that helps sentiment but the unchanged rating tempers immediate buying pressure. Mizuho PT Update
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a potential near‑term catalyst if management provides incremental guidance or color. Conference Notice
• Neutral Sentiment: Short‑interest data in recent reports appears anomalous (reports show zero / NaN changes) — treat those short‑interest updates as reporting noise rather than a real short‑squeeze signal.
• Negative Sentiment: Recent fundamentals still show friction: Q4 report (Feb. 26) included a slight EPS miss ($0.27 vs. $0.28) and a negative net margin, reminders that profitability and margin recovery remain key risks for longer‑term upside. MarketBeat XRAY summary

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.